Transforming growth factor beta mRNA (TGFB mRNA)

Transforming growth factor beta (TGF-beta) mRNA serves as the template for the synthesis of TGF-beta cytokines, which are critical regulators of cell growth, differentiation, and immune function (UniProt: P01137, P61812). In many pathological states, particularly advanced cancers and fibrotic disorders, the overproduction of TGF-beta isoforms (TGF-beta 1, 2, and 3) promotes disease progression by inducing epithelial-mesenchymal transition (EMT), stimulating extracellular matrix deposition, and suppressing the host immune response (PubMed: 23027052). Therapeutic strategies targeting TGF-beta mRNA utilize antisense oligonucleotides (ASOs) or RNA interference (RNAi) to selectively silence the expression of specific isoforms, most notably TGF-beta 2. By reducing the levels of these potent immunosuppressive and pro-fibrotic factors at the translational level, these therapies aim to restore anti-tumor immunity and inhibit tissue scarring. Clinical candidates like Trabedersen have been investigated for their ability to improve survival in patients with high-grade gliomas and other solid tumors by neutralizing the TGF-beta-mediated molecular shield (PubMed: 18454171).

Other names

TGF-beta mRNATGFB1 mRNATGFB2 mRNATGFB3 mRNATransforming growth factor beta 2 mRNA

Antisense oligonucleotides (ASOs) or siRNA molecules bind to the target TGF-beta mRNA through complementary base pairing, which either triggers enzymatic degradation of the mRNA transcript (e.g., via RNase H) or physically blocks the translation machinery, resulting in decreased protein synthesis (PubMed: 16467104).